VivoSeq
Oncology

Biliary Tract Neoplasm

15

Pipeline Programs↗

0

Active Trials↗

12

Companies Involved↗

Biliary Tract Neoplasm is an emerging landscape with 15 programs across 12 companies. The most active players are Coherus Oncology, Inc., Merck & Co., BeiGene. 7 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Coherus Oncology, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

9 of 15 classified programs — the dominant modality here.

40%ALL OTHERSMonoclonal antibody640%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)